Eli Lilly Zepbound is the brand name for tirzepatide when prescribed for chronic weight management. The FDA approved it in November 2023, making it the first dual GLP-1/GIP receptor agonist available for obesity treatment. This article provides informational context about the drug, its manufacturer, and what patients and caregivers should know.
About Eli Lilly, the Manufacturer
Eli Lilly and Company is a pharmaceutical firm headquartered in Indianapolis, Indiana, founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and veteran of the U.S. Civil War. The company has roughly 43,000 employees worldwide and is one of the oldest pharmaceutical manufacturers in the United States. Lilly produces a wide range of medications including insulin (Humalog), cancer therapies, and diabetes drugs.
Zepbound and its diabetes counterpart Mounjaro contain the same active ingredient, tirzepatide. The molecule activates both GLP-1 and GIP receptors — a dual mechanism that has produced weight-loss results exceeding prior single-hormone drugs.
FDA Approval and Indication
According to the FDA’s November 2023 announcement, Zepbound is approved for adults with:
- Body mass index (BMI) of 30 kg/m² or greater (obesity), OR
- BMI of 27 kg/m² or greater (overweight) plus at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol
It is intended for use alongside a reduced-calorie diet and increased physical activity. It is not approved for cosmetic weight loss in people without these conditions.
How Tirzepatide Works
Tirzepatide activates two gut-hormone receptors simultaneously:
- GLP-1 receptor: Slows gastric emptying, increases insulin release after meals, reduces appetite by acting on brain hunger centers.
- GIP receptor: Enhances insulin response and may improve how fat tissue stores and handles energy.
The dual action may be why tirzepatide consistently outperforms GLP-1-only drugs like semaglutide in head-to-head trials. To learn more about this hormone class, see our prediabetes overview.
Dosing Schedule
| Period | Dose | Purpose |
|---|---|---|
| Weeks 1-4 | 2.5 mg weekly | Starting dose for tolerance |
| Weeks 5-8 | 5 mg weekly | First maintenance option |
| Weeks 9-12 | 7.5 mg weekly | Titration |
| Weeks 13-16 | 10 mg weekly | Second maintenance option |
| Weeks 17-20 | 12.5 mg weekly | Titration |
| Week 21+ | 15 mg weekly (max) | Highest maintenance dose |
Patients inject the drug subcutaneously once per week in the thigh, abdomen, or upper arm using a prefilled single-dose pen.
Clinical Trial Results
The NIH MedlinePlus drug information summarizes findings from the SURMOUNT-1 trial, which followed 2,539 adults with obesity or overweight (without diabetes) for 72 weeks:
- 5 mg dose: 15.0% mean weight loss
- 10 mg dose: 19.5% mean weight loss
- 15 mg dose: 20.9% mean weight loss
- Placebo: 3.1% mean weight loss
About 57 percent of patients on the 15 mg dose lost at least 20 percent of their starting body weight. Blood pressure, cholesterol, and waist circumference also improved significantly compared with placebo.
Side Effects
The most common side effects reported in clinical trials include:
- Nausea (25-31%)
- Diarrhea (19-23%)
- Vomiting (8-12%)
- Constipation (11-17%)
- Abdominal pain (9-10%)
- Fatigue (5-7%)
- Injection-site reactions (5-8%)
Serious but less common risks, per the FDA label, include pancreatitis, gallbladder disease, severe gastrointestinal problems, kidney injury, and potential thyroid C-cell tumors (based on rodent studies). Zepbound is contraindicated in people with medullary thyroid carcinoma or MEN 2 syndrome.
Cost and Access
The list price of Zepbound is approximately $1,060 for a one-month supply. Actual out-of-pocket cost depends on insurance coverage, which varies widely. Some commercial plans cover weight-loss drugs while Medicare currently does not. Eli Lilly offers a savings card that reduces cost for eligible commercially insured patients.
Before starting any weight-loss medication, it is worth reviewing the full landscape of available treatments with your doctor, including diet, exercise, behavioral therapy, and other medications.
Manufacturing and Supply
Eli Lilly has invested more than $5 billion since 2020 to expand tirzepatide production at facilities in Lebanon, Indiana, and Concord, North Carolina. Demand following the 2023 Zepbound launch triggered intermittent supply shortages on certain dose strengths, reported on the FDA drug-shortage database. Lilly announced in late 2024 that all Zepbound doses had been restored to shelf availability for U.S. pharmacies, though regional gaps can still occur.
Zepbound ships in single-use, preloaded pens containing one weekly dose each. The pens require refrigeration between 36 to 46 degrees Fahrenheit before first use and must be discarded after 21 days at room temperature or past the labeled expiration date, whichever comes first.
How Zepbound Fits Into a Broader Plan
The FDA label emphasizes that Zepbound is approved only alongside a reduced-calorie diet and increased physical activity — not as a standalone solution. Clinical trial protocols required participants to follow nutrition counseling and aim for at least 150 minutes of moderate exercise weekly. Patients who pair Zepbound with strong lifestyle habits tend to retain more muscle mass and better long-term outcomes than those relying on the drug alone.
If you discontinue the medication, expect to regain a meaningful share of the weight lost unless habits have firmly replaced what the drug was doing for appetite. Many clinicians now treat obesity as a chronic condition requiring long-term therapy, similar to how hypertension or hypothyroidism is managed.
The Bottom Line
Eli Lilly Zepbound is an FDA-approved prescription medication containing tirzepatide, designed for chronic weight management in adults with obesity or overweight plus a related health condition. Clinical data show substantial weight loss, though side effects and cost are real considerations. This article is informational and not a recommendation. Talk with your healthcare provider to determine whether Zepbound, another medication, or lifestyle changes best fit your situation.
Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor before starting any prescription medication.
